34
66
Growth Score
-2 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
309442
Synkrino Biotherapeutics is a biotech platform that discovers and develops novel drug targets directly from the immune system of patients.
Jason Barbour: Co-Founder and CEO- David Ott: CTO and Co-Founder
About the Company
Synkrino Biotherapeutics is a biotech platform that discovers and develops novel drug targets directly from the immune system of patients. The platform is providing monitoring for pediatric rheumatologists for life-threatening conditions. It is currently building a rapid, portable field test for the RNA virus 2019-nCoV/COVID-19, adapting its
existing analytic protocols for community public health screening.
Synkrino Biotherapeutics' therapeutics use AI + Immunology Discovery Engine (AIDE Engine) which applies neural networks and machine learning to measure the immune tissue from patients to repeatably discover novel and biologically-valid drug targets, enabling healthcare providers to cure their patients and improve their lives.
